Pfizer Says CDC's Advisory Committee On Immunization Practice Voted To Expand Recommendation For Use Of Certain Pneumococcal Vaccines, Including PREVNAR 20 For All Adults Aged 50 And Older
Portfolio Pulse from Benzinga Newsdesk
Pfizer announced that the CDC's Advisory Committee on Immunization Practice has voted to expand the recommendation for the use of certain pneumococcal vaccines, including PREVNAR 20, for all adults aged 50 and older.
October 23, 2024 | 8:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The CDC's Advisory Committee has expanded the recommendation for Pfizer's PREVNAR 20 vaccine to include all adults aged 50 and older. This expansion could lead to increased sales and revenue for Pfizer.
The expanded recommendation by the CDC for PREVNAR 20 to include adults aged 50 and older is likely to increase the market size for this vaccine. This could result in higher sales and revenue for Pfizer, positively impacting its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90